Attention-deficit/hyperactivity disorder pharmacogenomics.
about
Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorderAdvances in understanding and treating ADHDTwo CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basisImmunologic and neurodevelopmental susceptibilities of autismADHD and smoking: from genes to brain to behaviorDopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorderCo-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment.Parent-child DRD4 genotype as a potential biomarker for oppositional, anxiety, and repetitive behaviors in children with autism spectrum disorderPossible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorderDopamine transporter 3'-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate.Occupational issues of adults with ADHD.Advances in genetic findings on attention deficit hyperactivity disorder.Rodent versions of the iowa gambling task: opportunities and challenges for the understanding of decision-making.Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.Drug therapy of attention deficit hyperactivity disorder: current trends.Innovations and recent trends in the treatment of ADHD.The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy.Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder.Clinical pharmacogenetics in pediatric patients.Pharmacogenetics in psychiatry: are we ready for widespread clinical use?Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHDThe potential impact of pharmacogenetic testing on medication adherenceCognitive enhancement by drugs in health and diseaseRole of COMT in ADHD: a systematic meta-analysis.Association of maternal dopamine transporter genotype with negative parenting: evidence for gene x environment interaction with child disruptive behavior.Current issues and trends in the diagnosis and treatment of adults with ADHD.DAT1 methylation is associated with methylphenidate response on oppositional and hyperactive-impulsive symptoms in children and adolescents with ADHD.Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive-compulsive disorder.The divergent impact of COMT Val158Met on executive function in children with and without attention-deficit/hyperactivity disorder.A brief DSM-IV-referenced teacher rating scale for monitoring behavioral improvement in ADHD and co-occurring symptoms.
P2860
Q22242334-6EF8BC38-B34C-4556-AE61-02E9530FBD64Q24601949-1256CFDF-B9FE-4D75-9AAE-C9B4FCDA6B38Q24655643-BED6103D-5194-4716-AC45-AF3AED449218Q28275427-28A555C0-56CF-4219-A8AB-BF25D5BAA84DQ28300210-440756F3-CE31-4CF2-AA49-75683FD16F60Q33799533-4EF8F01D-CD22-4A24-8498-D91D29F233A4Q33870580-9D443125-91DD-4E18-B3C5-44D7A6E26B3FQ33926699-36357143-C03A-447E-A9FA-8C27A66D225EQ34011138-BB35DBCF-A8F8-4C83-9BA8-38247E8A907CQ34126802-89F5C9F5-7C37-4C53-91E2-01F3BEB0F2E0Q34221423-6123719E-9CA9-4DDC-BD3B-E9277F70930AQ34576427-D93DACE5-D056-43A7-BDCD-CE18BF24BB5BQ34588668-A54D7F18-7BE5-4BAC-BABA-C13D8A2D37FEQ34628923-2CB43F43-1C44-46EA-9711-730F68DC5220Q35295664-C68320FA-80EC-4790-A8E4-50159D21C166Q35575795-B697479F-DD03-4E1C-B1D6-4FC5955CD5C6Q35964370-A0F49EB0-BC59-485C-9338-38A73A12D2FEQ36607357-E722FD95-6493-424E-8A79-7EDB4E8A3EC4Q36699910-CB67B2CF-323A-43BD-954F-61FF87FE7B11Q36787333-FB9F5885-8B9F-491E-BA12-AC996F6B183CQ36989836-B7BAC69B-2B3C-407D-B363-182BF6EA3943Q37076472-2FEA5A9D-789A-407B-9422-F6C013CF449CQ37275595-3A788A5B-7511-4FE3-9979-0EC85D613AA2Q37671210-650F2878-0E10-4857-8AB4-1486BDF93D0FQ37819134-696F7971-95DA-41F4-8E68-AF11B25DB379Q46162576-A026A6BA-838F-43A3-B106-9DDD2DEF0762Q46380295-D2927C8D-B673-4353-9839-B1778159EFE4Q46947976-6BFCD587-3BF9-4A36-8A9D-4C182A23DD20Q47927866-85A9474E-4BE5-4283-AA07-6B537F7C364DQ50507170-CDF28BBA-EE89-440E-9F03-AE62F8CF28C2Q50549895-A8DED78B-68A6-4ABF-98A9-6ADC698BC301Q51778460-5B75D1F1-8257-475A-AF6B-C00B7D24D5ED
P2860
Attention-deficit/hyperactivity disorder pharmacogenomics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Attention-deficit/hyperactivity disorder pharmacogenomics.
@ast
Attention-deficit/hyperactivity disorder pharmacogenomics.
@en
type
label
Attention-deficit/hyperactivity disorder pharmacogenomics.
@ast
Attention-deficit/hyperactivity disorder pharmacogenomics.
@en
prefLabel
Attention-deficit/hyperactivity disorder pharmacogenomics.
@ast
Attention-deficit/hyperactivity disorder pharmacogenomics.
@en
P1476
Attention-deficit/hyperactivity disorder pharmacogenomics.
@en
P2093
James J McGough
P304
P356
10.1016/J.BIOPSYCH.2004.10.021
P407
P577
2005-01-05T00:00:00Z